China's COVID vaccines have been crucial - now immunity is waning.

  title={China's COVID vaccines have been crucial - now immunity is waning.},
  author={Smriti Mallapaty},
Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study
Significant increases in the risk of moderate and severe covid-19 outcomes occurred three months after primary vaccination with CoronaVac among people aged 65 and older, providing supportive evidence for the implementation of vaccine boosters in these populations who received this inactivated vaccine.
Conceptualizing “the end” of COVID-19: temporality and linear mobilization toward health
ABSTRACT COVID-19 has crystalized how Western sociopolitical, cultural, and biomedical understandings of health advance the spaciotemporal logic of “the end.” This logic defines health in terms of
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
Administration of the third dose with either viral vector or mRNA vaccine for the BBIBP-CorV-primed individuals to stimulate antibody and T cell responses is supported.
Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?
The evidence for efficacy of face mask wearing in various settings is reviewed and overall pooled analysis showed significant reduction in COVID‐19 incidence with mask wearing, although heterogeneity between studies was substantial.
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2.
Effectiveness in preventing hospitalizations, ICU admissions, and deaths was more prominent than that in preventing COVID-19, and three-dose regimen significantly increased the seroconversion levels of neutralizing antibodies against omicron as compared to two- dose regimen.
Chest X-Ray Description Of Vaccinated And Unvaccinated Covid-19 Patients: Case Study
As Covid-19 cases increase and transmission accelerates, it is more likely that new more contagious variants emerge, may spread more easily. Chest X-Rays examination performed during the Covid-19
Advances in COVID-19 Vaccines and New Coronavirus Variants
An overview of the most prevalent coronavirus variants including Omicron is provided, and the effectiveness of COVID-19 vaccines against related variants is explored to better understand existing vaccines and to facilitate improved research into new vaccines.
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
The results support the use of both vaccines in adolescents and find higher S, neutralising, avidity and Fc receptor-binding antibody responses in adolescents receiving BB than CC, and a similar induction of strong S-specific T cells by the 2 vaccines, possibly implying differential durability and cross-variant protection.


Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Insight is provided into the generation of long-term immunological memory by the inactivated vaccine, which could be rapidly recalled and further boosted by a third dose, and robust expansion of memory pools by the third dose potentiated greater durability of protective immune responses.
Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases
Despite varying effectiveness estimates, Brazil's population benefited from vaccination in preventing severe COVID-19 outcomes, suggesting significant vaccine-specific reductions in effectiveness by age, given by differences between age groups 60-79 years and over 80 years.
Heterologous prime-boost immunization with CoronaVac and Convidecia
The heterologous prime-boost regimen with Convidecia after the priming with CoronaVac was safe and significantly immunogenic than a homogeneous boost with Coronavac.
Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
Combination use of different available vaccines may be warranted in Thailand, which faces limited vaccine choice and supply, because of delayed mass-immunization of COVID-19 vaccines.
Short-Term Immune Response After Inactivated SARS-CoV-2 (CoronaVac, Sinovac) And ChAdOx1 nCoV-19 (Vaxzevria, Oxford-AstraZeneca) Vaccinations in Thai Health Care Workers
A rapid decline of short-term immune response in the HCWs after the SV vaccination indicates the need for a vaccine booster, particularly during the ongoing spreading of the SAR-CoV-2 variants of concern.
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong
Few head‐to‐head evaluations of immune responses to different vaccines have been reported, but these evaluations are likely to have important implications for the design of vaccine safety and effectiveness.
The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19).
The results suggest that individuals aged 90 years or older may benefit from an expedited third booster dose, and both vaccines demonstrated overall effectiveness against severe COVID-19 up to 80 years of age.
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Importance: Whether herd immunity through mass vaccination is sufficient to curb SARS-CoV-2 transmission requires an understanding of the duration of vaccine-induced immunity, and the necessity and